A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.
Publication
, Journal Article
Held, LA; Rizzieri, D; Long, GD; Gockerman, JP; Diehl, LF; de Castro, CM; Moore, JO; Horwitz, ME; Chao, NJ; Gasparetto, C
Published in: Cancer Invest
March 2013
PURPOSE: This Phase I study assessed the feasibility of concomitant arsenic trioxide (ATO), ascorbic acid (AA), and bortezomib (Velcade™) (AAV) for patients with relapsed/refractory multiple myeloma. EXPERIMENTAL DESIGN: ATO (0.25 mg/kg) and AA (1 g) were given with an escalating dose of bortezomib (1 mg/m(2) or 1.3 mg/m(2) IV bolus on days 1 and 8 of a 21-day cycle). RESULTS: Ten patients (median age 62 years), with a median of 3 prior regimens, were enrolled. Four (40%) patients achieved clinical benefit, with one patient achieving a durable partial response. No formal DLTs were encountered. CONCLUSION: AAV combination was feasible and demonstrated some benefits in this heavily pretreated population.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Cancer Invest
DOI
EISSN
1532-4192
Publication Date
March 2013
Volume
31
Issue
3
Start / End Page
172 / 176
Location
England
Related Subject Headings
- Recurrence
- Pyrazines
- Oxides
- Oncology & Carcinogenesis
- Multiple Myeloma
- Middle Aged
- Male
- Humans
- Female
- Bortezomib
Citation
APA
Chicago
ICMJE
MLA
NLM
Held, L. A., Rizzieri, D., Long, G. D., Gockerman, J. P., Diehl, L. F., de Castro, C. M., … Gasparetto, C. (2013). A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma. Cancer Invest, 31(3), 172–176. https://doi.org/10.3109/07357907.2012.756109
Held, Lauren A., David Rizzieri, Gwynn D. Long, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, Joseph O. Moore, Mitchell E. Horwitz, Nelson J. Chao, and Cristina Gasparetto. “A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.” Cancer Invest 31, no. 3 (March 2013): 172–76. https://doi.org/10.3109/07357907.2012.756109.
Held LA, Rizzieri D, Long GD, Gockerman JP, Diehl LF, de Castro CM, et al. A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma. Cancer Invest. 2013 Mar;31(3):172–6.
Held, Lauren A., et al. “A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.” Cancer Invest, vol. 31, no. 3, Mar. 2013, pp. 172–76. Pubmed, doi:10.3109/07357907.2012.756109.
Held LA, Rizzieri D, Long GD, Gockerman JP, Diehl LF, de Castro CM, Moore JO, Horwitz ME, Chao NJ, Gasparetto C. A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma. Cancer Invest. 2013 Mar;31(3):172–176.
Published In
Cancer Invest
DOI
EISSN
1532-4192
Publication Date
March 2013
Volume
31
Issue
3
Start / End Page
172 / 176
Location
England
Related Subject Headings
- Recurrence
- Pyrazines
- Oxides
- Oncology & Carcinogenesis
- Multiple Myeloma
- Middle Aged
- Male
- Humans
- Female
- Bortezomib